Primary CNS lymphoma of T-cell origin: A descriptive analysis from the international primary CNS Lymphoma Collaborative Group

Tamara N. Shenkier, Jean Yves Blay, Brian Patrick O'Neill, Philip Poortmans, Eckhard Thiel, Kristoph Jahnke, Lauren E. Abrey, Edward Neuwelt, Richard Tsang, Tracy Batchelor, Nancy Harris, Andrés J M Ferreri, Maurilio Ponzoni, Peter O'Brien, James Rubenstein, Joseph M. Connors

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

Purpose: To describe the demographic and tumor related characteristics and outcomes for patients with primary T-cell CNS lymphoma (TPCNSL). Patients and Methods: A retrospective series of patients with TPCNSL was compiled from twelve cancer centers in seven countries. Results: We identified 45 patients with a median age of 60 years (range, 3 to 84 years). Twenty (44%) had Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. Twenty-six (58%) had involvement of a cerebral hemisphere and sixteen (36%) had lesions of deeper sites in the brain. Serum lactate dehydrogenase was elevated in 7 (32%) of 22 patients, and CSF protein was elevated in 19 of 24 patients (79%) with available data. The median disease-specific survival (DSS) was 25 months (95% CI, 11 to 38 months). The 2- and 5-year DSS were 51% (95% CI, 35% to 66%) and 17% (95% CI, 6% to 34%), respectively. Univariate and multivariate analyses were conducted for age (≤ 60 v > 60 years), PS (0 or 1 v 2, 3, or 4), involvement of deep structures of the CNS (no v yes), and methotrexate (MTX) use in the primary treatment (yes v no). Only PS and MTX use were significantly associated with better outcome with hazard ratios of 0.2 (95% CI, 0.1 to 0.4) and 0.4 (95% CI, 0.2 to 0.8), respectively. Conclusion: This is the largest series ever assembled of TPCNSL. The presentation and outcome appear similar to that of B cell PCNSL. PS 0 or 1 and administration of MTX are associated with better survival.

Original languageEnglish (US)
Pages (from-to)2233-2239
Number of pages7
JournalJournal of Clinical Oncology
Volume23
Issue number10
DOIs
StatePublished - 2005
Externally publishedYes

Fingerprint

T-Cell Lymphoma
Lymphoma
Methotrexate
Survival
Cerebrum
L-Lactate Dehydrogenase
Neoplasms
B-Lymphocytes
Multivariate Analysis
Demography
Brain
Serum
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Shenkier, T. N., Blay, J. Y., O'Neill, B. P., Poortmans, P., Thiel, E., Jahnke, K., ... Connors, J. M. (2005). Primary CNS lymphoma of T-cell origin: A descriptive analysis from the international primary CNS Lymphoma Collaborative Group. Journal of Clinical Oncology, 23(10), 2233-2239. https://doi.org/10.1200/JCO.2005.07.109

Primary CNS lymphoma of T-cell origin : A descriptive analysis from the international primary CNS Lymphoma Collaborative Group. / Shenkier, Tamara N.; Blay, Jean Yves; O'Neill, Brian Patrick; Poortmans, Philip; Thiel, Eckhard; Jahnke, Kristoph; Abrey, Lauren E.; Neuwelt, Edward; Tsang, Richard; Batchelor, Tracy; Harris, Nancy; Ferreri, Andrés J M; Ponzoni, Maurilio; O'Brien, Peter; Rubenstein, James; Connors, Joseph M.

In: Journal of Clinical Oncology, Vol. 23, No. 10, 2005, p. 2233-2239.

Research output: Contribution to journalArticle

Shenkier, TN, Blay, JY, O'Neill, BP, Poortmans, P, Thiel, E, Jahnke, K, Abrey, LE, Neuwelt, E, Tsang, R, Batchelor, T, Harris, N, Ferreri, AJM, Ponzoni, M, O'Brien, P, Rubenstein, J & Connors, JM 2005, 'Primary CNS lymphoma of T-cell origin: A descriptive analysis from the international primary CNS Lymphoma Collaborative Group', Journal of Clinical Oncology, vol. 23, no. 10, pp. 2233-2239. https://doi.org/10.1200/JCO.2005.07.109
Shenkier, Tamara N. ; Blay, Jean Yves ; O'Neill, Brian Patrick ; Poortmans, Philip ; Thiel, Eckhard ; Jahnke, Kristoph ; Abrey, Lauren E. ; Neuwelt, Edward ; Tsang, Richard ; Batchelor, Tracy ; Harris, Nancy ; Ferreri, Andrés J M ; Ponzoni, Maurilio ; O'Brien, Peter ; Rubenstein, James ; Connors, Joseph M. / Primary CNS lymphoma of T-cell origin : A descriptive analysis from the international primary CNS Lymphoma Collaborative Group. In: Journal of Clinical Oncology. 2005 ; Vol. 23, No. 10. pp. 2233-2239.
@article{74e05c5fb8ea47ab8e9905d8317e2307,
title = "Primary CNS lymphoma of T-cell origin: A descriptive analysis from the international primary CNS Lymphoma Collaborative Group",
abstract = "Purpose: To describe the demographic and tumor related characteristics and outcomes for patients with primary T-cell CNS lymphoma (TPCNSL). Patients and Methods: A retrospective series of patients with TPCNSL was compiled from twelve cancer centers in seven countries. Results: We identified 45 patients with a median age of 60 years (range, 3 to 84 years). Twenty (44{\%}) had Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. Twenty-six (58{\%}) had involvement of a cerebral hemisphere and sixteen (36{\%}) had lesions of deeper sites in the brain. Serum lactate dehydrogenase was elevated in 7 (32{\%}) of 22 patients, and CSF protein was elevated in 19 of 24 patients (79{\%}) with available data. The median disease-specific survival (DSS) was 25 months (95{\%} CI, 11 to 38 months). The 2- and 5-year DSS were 51{\%} (95{\%} CI, 35{\%} to 66{\%}) and 17{\%} (95{\%} CI, 6{\%} to 34{\%}), respectively. Univariate and multivariate analyses were conducted for age (≤ 60 v > 60 years), PS (0 or 1 v 2, 3, or 4), involvement of deep structures of the CNS (no v yes), and methotrexate (MTX) use in the primary treatment (yes v no). Only PS and MTX use were significantly associated with better outcome with hazard ratios of 0.2 (95{\%} CI, 0.1 to 0.4) and 0.4 (95{\%} CI, 0.2 to 0.8), respectively. Conclusion: This is the largest series ever assembled of TPCNSL. The presentation and outcome appear similar to that of B cell PCNSL. PS 0 or 1 and administration of MTX are associated with better survival.",
author = "Shenkier, {Tamara N.} and Blay, {Jean Yves} and O'Neill, {Brian Patrick} and Philip Poortmans and Eckhard Thiel and Kristoph Jahnke and Abrey, {Lauren E.} and Edward Neuwelt and Richard Tsang and Tracy Batchelor and Nancy Harris and Ferreri, {Andr{\'e}s J M} and Maurilio Ponzoni and Peter O'Brien and James Rubenstein and Connors, {Joseph M.}",
year = "2005",
doi = "10.1200/JCO.2005.07.109",
language = "English (US)",
volume = "23",
pages = "2233--2239",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - Primary CNS lymphoma of T-cell origin

T2 - A descriptive analysis from the international primary CNS Lymphoma Collaborative Group

AU - Shenkier, Tamara N.

AU - Blay, Jean Yves

AU - O'Neill, Brian Patrick

AU - Poortmans, Philip

AU - Thiel, Eckhard

AU - Jahnke, Kristoph

AU - Abrey, Lauren E.

AU - Neuwelt, Edward

AU - Tsang, Richard

AU - Batchelor, Tracy

AU - Harris, Nancy

AU - Ferreri, Andrés J M

AU - Ponzoni, Maurilio

AU - O'Brien, Peter

AU - Rubenstein, James

AU - Connors, Joseph M.

PY - 2005

Y1 - 2005

N2 - Purpose: To describe the demographic and tumor related characteristics and outcomes for patients with primary T-cell CNS lymphoma (TPCNSL). Patients and Methods: A retrospective series of patients with TPCNSL was compiled from twelve cancer centers in seven countries. Results: We identified 45 patients with a median age of 60 years (range, 3 to 84 years). Twenty (44%) had Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. Twenty-six (58%) had involvement of a cerebral hemisphere and sixteen (36%) had lesions of deeper sites in the brain. Serum lactate dehydrogenase was elevated in 7 (32%) of 22 patients, and CSF protein was elevated in 19 of 24 patients (79%) with available data. The median disease-specific survival (DSS) was 25 months (95% CI, 11 to 38 months). The 2- and 5-year DSS were 51% (95% CI, 35% to 66%) and 17% (95% CI, 6% to 34%), respectively. Univariate and multivariate analyses were conducted for age (≤ 60 v > 60 years), PS (0 or 1 v 2, 3, or 4), involvement of deep structures of the CNS (no v yes), and methotrexate (MTX) use in the primary treatment (yes v no). Only PS and MTX use were significantly associated with better outcome with hazard ratios of 0.2 (95% CI, 0.1 to 0.4) and 0.4 (95% CI, 0.2 to 0.8), respectively. Conclusion: This is the largest series ever assembled of TPCNSL. The presentation and outcome appear similar to that of B cell PCNSL. PS 0 or 1 and administration of MTX are associated with better survival.

AB - Purpose: To describe the demographic and tumor related characteristics and outcomes for patients with primary T-cell CNS lymphoma (TPCNSL). Patients and Methods: A retrospective series of patients with TPCNSL was compiled from twelve cancer centers in seven countries. Results: We identified 45 patients with a median age of 60 years (range, 3 to 84 years). Twenty (44%) had Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. Twenty-six (58%) had involvement of a cerebral hemisphere and sixteen (36%) had lesions of deeper sites in the brain. Serum lactate dehydrogenase was elevated in 7 (32%) of 22 patients, and CSF protein was elevated in 19 of 24 patients (79%) with available data. The median disease-specific survival (DSS) was 25 months (95% CI, 11 to 38 months). The 2- and 5-year DSS were 51% (95% CI, 35% to 66%) and 17% (95% CI, 6% to 34%), respectively. Univariate and multivariate analyses were conducted for age (≤ 60 v > 60 years), PS (0 or 1 v 2, 3, or 4), involvement of deep structures of the CNS (no v yes), and methotrexate (MTX) use in the primary treatment (yes v no). Only PS and MTX use were significantly associated with better outcome with hazard ratios of 0.2 (95% CI, 0.1 to 0.4) and 0.4 (95% CI, 0.2 to 0.8), respectively. Conclusion: This is the largest series ever assembled of TPCNSL. The presentation and outcome appear similar to that of B cell PCNSL. PS 0 or 1 and administration of MTX are associated with better survival.

UR - http://www.scopus.com/inward/record.url?scp=20244383617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244383617&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.07.109

DO - 10.1200/JCO.2005.07.109

M3 - Article

C2 - 15800313

AN - SCOPUS:20244383617

VL - 23

SP - 2233

EP - 2239

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -